December 19, 2024

FDA Resolves Lilly Drug Shortage Issue

The FDA has addressed the shortage of Eli Lilly's weight-loss drug and a lawsuit involving compounding pharmacies. Novo Nordisk's weight-loss drug remains in short supply.

Reuters

December 19, 2024

FDA Redefines 'Healthy' Food Claims

The regulation requires qualifying foods to contain amounts from at least one food group or subgroup referenced in the Dietary Guidelines for Americans.

Conexiant

December 18, 2024

USPSTF Challenges Common Supplement Use

"Unfortunately, when we reviewed the latest evidence, we found that taking vitamin D with or without calcium does not prevent falls or fractures in older adults."

Conexiant

December 18, 2024

Does Anger at Health Care Drive Change?

In-depth exploration of public anger towards the American health care system throughout history, potential for change, and Hollywood's portrayal of health insurance-related events.

KFF Health News

December 17, 2024

New TED Drug Positioned for Success

A groundbreaking late-stage study highlights the effectiveness of Viridian Therapeutics' novel treatment, veligrotug, for chronic thyroid eye disease, offering hope for more convenient and efficient therapy. Positive results led to a substantial boost in the company's stock price.

Reuters

December 17, 2024

FDA Targets Unapproved GLP-1 Drug Sellers

The FDA has issued warning letters to companies for selling unapproved versions of popular diabetes and weight-loss drugs. The companies falsely labeled products for 'research use only' despite evidence showing they are intended for human use.

Reuters

December 16, 2024

Does Ozempic Double Eye Disease Risk?

Danish health authorities seek EU review of studies linking Novo Nordisk's Ozempic to rare eye condition in type 2 diabetes patients.

Reuters

December 16, 2024

FDA 6-Month Drug Pipeline

A pipeline of novel drugs awaits FDA review through the first half of 2025.

Conexiant

December 16, 2024

Weight-Loss Drugs Spark Health Care Shift

An exclusive analysis reveals the impact of weight-loss drugs on obesity-related conditions, leading to increased diagnoses of sleep apnea, cardiovascular disease, and type 2 diabetes within days of treatment initiation.

Reuters